



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Road,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Company Update and EOFY 2023 Information

Melbourne, 4 Aug 2023: Australian vaccine development company BioDiem Ltd today and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following update.

Live attenuated flu virus (LAIV) vaccine

China-based Changchun BCHT Biotechnology Co (BCHT) holds an exclusive licence from BioDiem for the vaccine technology based on the live attenuated influenza virus (LAIV). BCHT’s licence covers the private sector market in China for pandemic and seasonal influenza vaccines made using an egg-based production method. BCHT holds a complementary licence to the LAIV for the public market in China via a sublicense from the World Health Organisation. BioDiem received a payment from BCHT of US\$241,852 in February 2023.

Opal Biosciences Ltd (“Opal”)

- On 21 June Opal announced its proposed merger with specialist company, Formulytica Pty Ltd (“Formulytica”).
- On 18 July 2023 Opal announced it had been awarded an Investment Attraction Fund grant of \$5m by the Government of Western Australia. The grant will support establishment of a manufacturing facility in Perth to develop and formulate the materials required for use in clinical trials particularly small batch manufacture of sterile injectables and vaccines.
- On 31 July 2023 Opal lodged an MRFF National Critical Infrastructure grant application requesting \$5m to support the Perth facility and a program to manufacture personalised medicines.

EOFY Share Price information*

The EOFY 2023 share price information is as follows being the pricing of the last capital raise:

- BioDiem ordinary shares = \$0.08 (8 cents)
- BioDiem preference shares = \$0.08 (8 cents)

For those BioDiem shareholders who also separately hold shares in Opal, the EOFY 2023 share price of Opal Biosciences ordinary shares is \$0.075 (7.5 cents) being the pricing of the last capital raise.

*The Company does not provide any advice regarding valuation, and shareholders are encouraged to seek their own professional advice in relation to valuation of their shares.

Shareholder Information at Share Registry, Computershare.

Shareholders are asked to ensure their contact details/email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre (www.computershare.com.au).

- ENDS -

Further information

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9692 7240
Email jphillips@biodiem.com